LSBCF (LakeShore Biopharma Co) Buyback Yield %: 0.00 (As of Jun. 27, 2026)


What is LakeShore Biopharma Co Buyback Yield %?

LakeShore Biopharma Co LSBCF Buyback Yield % is 0.00 as of Jun. 27, 2026. The stock has 5 warning signs investors should review. Among 743 Biotechnology companies, LakeShore Biopharma Co ranks worse than 134589.37% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

LakeShore Biopharma Co's current buyback yield was 0.00%.

LakeShore Biopharma Co Buyback Yield % Historical Data

* Premium members only.

The historical data trend for LakeShore Biopharma Co's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LakeShore Biopharma Co Buyback Yield % Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Buyback Yield %
0.00 0.00 0.00 -28.82 0.00

LakeShore Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25
Buyback Yield % Get a 7-Day Free Trial Premium Member Only 0.00 0.00 -28.82 0.00 0.00

LSBCF vs ACUT, PPCB, ENSC: Buyback Yield % Comparison

For the Biotechnology subindustry, LakeShore Biopharma Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LakeShore Biopharma Co Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LakeShore Biopharma Co's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where LakeShore Biopharma Co's Buyback Yield % falls into.


LakeShore Biopharma Co Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

LakeShore Biopharma Co's Buyback Yield for the fiscal year that ended in Mar. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 50.87915
=0.00%

LakeShore Biopharma Co's annualized Buyback Yield for the quarter that ended in Mar. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 50.87915
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
LakeShore Biopharma Co (LSBCF) has a Buyback Yield % of 0.00 as of Jun. 27, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on LakeShore Biopharma Co and its competitors. According to the industry distribution chart, LakeShore Biopharma Co ranks #999999 out of 743 companies in the Biotechnology industry.
Is LakeShore Biopharma Co's Buyback Yield % too high?
LakeShore Biopharma Co's current Buyback Yield % is 0.00. Based on the distribution chart, LakeShore Biopharma Co ranks #999999 out of 743 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does LakeShore Biopharma Co's Buyback Yield % compare to ACUT and PPCB?
According to the Biotechnology industry distribution chart, LakeShore Biopharma Co ranks #999999 out of 743 companies for Buyback Yield %. This places LakeShore Biopharma Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on LakeShore Biopharma Co and its competitors. LakeShore Biopharma Co's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LakeShore Biopharma Co stock overvalued right now?
LakeShore Biopharma Co (LSBCF) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For LakeShore Biopharma Co (LSBCF), the current Buyback Yield % is 0.00 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LakeShore Biopharma Co Business Description

Address 38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.